

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (Review of TA573) [ID4057]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Janssen (daratumumab) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> Bloodwise Myeloma UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Cancer Physicians Cancer Research UK Royal College of Physicians Royal College of Radiologists UK Myeloma Forum <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health NHS England Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Amgen (carfilzomib) Celgene (lenalidomide and pomalidomide) Concordia International (dexamethasone) Janssen (bortezomib, daratumumab and doxorubicin) Novartis (panobinostat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> Bloodwise Institute of Cancer Research National Cancer Research Institute <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> Public Health England Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and

National Institute for Health and Care Excellence

Final matrix for the single technology appraisal of daratumumab in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID974]

those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.